Efficacy of montelukast in the treatment of children with cough variant asthma

Objective To observe the efficacy of Montelukast in the treatment of children with cough variant asthma(CVA) and to provide theoretical basis for alternative hormone treatment to asthma.Methods Eighty six children with CVA in accordance with our standards were chosen and divided into control group and observation group according to random digits table with 43 patients respectively.Patients in the control group were given Budesonide and Terbutaline treatment while patients in the observation group were given Montelukast plus Terbutaline treatment.Patients were treated for 3 months and 6 months follow-up.Symptoms and lung function indicators of the patients were measured before and after treatment.Symptomatic relief time and recurrence rate was recorded and compared.Adverse effects were recorded to evaluate clinical efficacy.Results(1)No statistically significant differences(χ2 = 0.367,P 0.05) existed in total effective rate in which observation group and control group showed 93.02% and 95.35% respectively.(2) Symptomatic relief time and recurrence rate of the observation group and the control group were(5.6 ±2.5) d,(5.3±3.0) d,6.98% and 6.98% respectively,no statistically significant differences(P 0.05) existed;forced expiratory volume in one second percentage of predicted(FEV1 %) and peak expiratory flow percentage of predicted(PEF%) level between the two groups during treatment didn't have statistically significant differences(P 0.05).(3)Adverse effect occurrence rate of observation group and control group was 0 and 9.30% respectively,statistically significant differences existed(χ2 = 4.195,P 0.05).Conclusion Montelukast and Budesonide has same efficacy in the treatment of children's CVA.Children taken Montelukast have better compliance and safety.Montelukast has alternative function to Glucocorticoid.